Iovance Biotherapeutics Announces Approval of First Clinical Trial Application by Competent Authority in Netherlands for a Phase 2 Trial of LN-145 for the Treatment of Patients with Cervical Cancer

World News: . []

SAN CARLOS, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the approval of the Company’s Clinical Trial Application (CTA), by the competent authority (CA) in the Netherlands, for a Phase 2 trial of LN-145 for the treatment of patients with recurrent, metastatic or persistent cervical carcinoma. Iovance initiated the submission of CTAs in multiple countries in Europe starting in August 2017 in support of clinical trials in cervical carcinoma and metastatic melanoma.

“We intend to use the data from our Phase 2 trials in support of global registration for TIL therapy to treat patients with melanoma and cervical carcinoma. We are very enthusiastic to have our first CTA approved by the CA and look forward to initiating our trials in Europe to offer TIL therapy to these metastatic melanoma and cervical carcinoma patients in addition to those in the US. The encouraging data generated by the National Cancer Institute showing responses in three of the nine cervical cancer patients treated with TIL therapy, with two continuing to have a complete response at 46 months and 54 months of follow up, supports the potential for LN-145 in the treatment of cervical cancer,” said Dr. Maria Fardis, PhD, MBA, President and Chief Executive Officer of Iovance Biotherapeutics.

LN-145 is an adoptive cell transfer (ACT) therapy that utilizes an autologous TIL manufacturing process. C-145-04 is a Phase 2, multicenter, single-arm, open-label interventional study that will enroll up to 47 patients and will assess the safety and efficacy of LN-145 for the treatment of patients with recurrent, metastatic, or persistent cervical carcinoma. The cell transfer therapy used in this study involves patients receiving a non-myeloablative (NMA) lymphocyte depleting preparative regimen, followed by infusion of autologous TIL and the administration of a regimen of up to six doses of IL-2.

More news and information about Iovance Biotherapeutics, Inc.

Published By:

Globe Newswire: 13:00 GMT Wednesday 13th September 2017

Published: .

Search for other references to "iovance" on SPi News

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2017. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers